Current treatment options in psoriasis

Hospital Practice

Volumn 31, Issue 4, 1996, Pages 155-166

  Phillips, Tania J ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EMOLLIENT AGENT; ETRETINATE; METHOTREXATE; METHOXSALEN; PHOTOSENSITIZING AGENT; PSORALEN; RETINOID; RETINOL;

ANOREXIA; ARTHRALGIA; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; HUMAN; HYPERTENSION; LEUKOPENIA; PATHOPHYSIOLOGY; PHOTOTHERAPY; PSORIASIS; PUVA; REVIEW; TOPICAL DRUG ADMINISTRATION; TOPICAL TREATMENT; ULTRAVIOLET B RADIATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PSORIASIS;

EID: 0029988605     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Ellis CN et al: Cyclosporine for plaque-type psoriasis: Results of amultidose, double blind trial. N Engl J Med 324:277, 1991
2. Gottlieb SL et al: Response of psoriasis to a lymphocyte-selective toxin (DAB389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1:442, 1995
3. Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 332:581, 1995
4. Leung DY et al: Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 96:2106, 1995
5. Roenigk HH Jr et al: Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 19:145, 1988
6. Stern RS et al: Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med 310:1156, 1984